34 related articles for article (PubMed ID: 38599885)
1. Sodium-glucose cotransporter-2 inhibitors and the risk of lung cancer among patients with type 2 diabetes.
Shapiro SB; Yin H; Yu OHY; Azoulay L
Br J Clin Pharmacol; 2024 May; 90(5):1365-1370. PubMed ID: 38477518
[TBL] [Abstract][Full Text] [Related]
2. Lower Atrial Fibrillation Risk With Sodium-Glucose Cotransporter 2 Inhibitors Than With Dipeptidyl Peptidase-4 Inhibitors in Individuals With Type 2 Diabetes: A Nationwide Cohort Study.
Kim M; Ha KH; Lee J; Park S; Oh KS; Bae DH; Lee JH; Kim SM; Choi WG; Hwang KK; Kim DW; Cho MC; Kim DJ; Bae JW
Korean Circ J; 2024 May; 54(5):256-267. PubMed ID: 38654455
[TBL] [Abstract][Full Text] [Related]
3. Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors.
Wysham CH; Lefebvre P; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Chow W; Pfeifer M; Duh MS
BMC Endocr Disord; 2017 Jun; 17(1):32. PubMed ID: 28595617
[TBL] [Abstract][Full Text] [Related]
4. The Benefits of Oral Glucose-Lowering Agents: GLP-1 Receptor Agonists, DPP-4 and SGLT-2 Inhibitors on Myocardial Ischaemia/Reperfusion Injury.
Huang XD; Jiang DS; Feng X; Fang ZM
Eur J Pharmacol; 2024 May; ():176698. PubMed ID: 38821168
[TBL] [Abstract][Full Text] [Related]
5. Association of Novel Antihyperglycemic Drugs Versus Metformin With a Decrease in Asthma Exacerbations.
Kimura Y; Jo T; Inoue N; Suzukawa M; Hashimoto Y; Kumazawa R; Ishimaru M; Matsui H; Yokoyama A; Tanaka G; Sasabuchi Y; Yasunaga H
J Allergy Clin Immunol Pract; 2024 May; ():. PubMed ID: 38734374
[TBL] [Abstract][Full Text] [Related]
6. More realistic power estimation for new user, active comparator studies: an empirical example.
Gokhale M; Buse JB; Pate V; Marquis MA; Stürmer T
Pharmacoepidemiol Drug Saf; 2016 Apr; 25(4):462-6. PubMed ID: 26360635
[TBL] [Abstract][Full Text] [Related]
7. Acute kidney injury, renal impairment and renal failure associated with sodium glucose co-transporter-2 inhibitors in at-risk groups: A systematic review.
Ziser KED; Livori AC; Morton JI; Prosser A; Ilomäki J; Wood SJ
Br J Clin Pharmacol; 2024 May; ():. PubMed ID: 38784979
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Wang Z; Sun J; Han R; Fan D; Dong X; Luan Z; Xiang R; Zhao M; Yang J
Diabetes Obes Metab; 2018 Jan; 20(1):113-120. PubMed ID: 28656707
[TBL] [Abstract][Full Text] [Related]
9. Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis.
Mishriky BM; Tanenberg RJ; Sewell KA; Cummings DM
Diabetes Metab; 2018 Mar; 44(2):112-120. PubMed ID: 29477373
[TBL] [Abstract][Full Text] [Related]
10. The association between sodium glucose cotransporter-2 inhibitors vs dipeptidyl peptidase-4 inhibitors and renal outcomes in people discharged from hospital with type 2 diabetes: A population-based cohort study.
Ziser KED; Wood S; Tan GSQ; Morton JI; Shaw JE; Bell JS; Ilomaki J
J Diabetes; 2024 Apr; 16(4):e13507. PubMed ID: 38599885
[TBL] [Abstract][Full Text] [Related]
11. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ
Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543
[TBL] [Abstract][Full Text] [Related]
12. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Atrial Fibrillation in Older Adults With Type 2 Diabetes.
Zhuo M; D'Andrea E; Paik JM; Wexler DJ; Everett BM; Glynn RJ; Kim SC; Patorno E
JAMA Netw Open; 2022 Oct; 5(10):e2235995. PubMed ID: 36219443
[TBL] [Abstract][Full Text] [Related]
13. A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes.
Fu EL; Mastrorilli J; Bykov K; Wexler DJ; Cervone A; Lin KJ; Patorno E; Paik JM
Kidney Int; 2024 Mar; 105(3):618-628. PubMed ID: 38101515
[TBL] [Abstract][Full Text] [Related]
14. Healthcare resource utilization after initiation of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors or other glucose-lowering drugs in Japanese patients with type 2 diabetes.
Kohsaka S; Takeda M; Kidani Y; Yajima T
Diabetes Obes Metab; 2021 Apr; 23 Suppl 2():28-39. PubMed ID: 33835640
[TBL] [Abstract][Full Text] [Related]
15. Comparison between sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors on the risk of incident cancer in patients with diabetes mellitus: A real-world evidence study.
Sung HL; Hung CY; Tung YC; Lin CC; Tsai TH; Huang KH
Diabetes Metab Res Rev; 2024 Mar; 40(3):e3784. PubMed ID: 38402457
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
